Cogent Biosciences (COGT) Current Assets (2017 - 2026)

Cogent Biosciences (COGT) has reported Current Assets for 10 consecutive years, with $877.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Assets rose 247.12% year-over-year to $877.8 million; the TTM figure through Mar 2026 stood at $877.8 million (up 247.12% YoY), while the FY2025 annual figure was $910.4 million, up 207.06% from the prior year.
• Current Assets declined to $877.8 million in Q1 2026 per COGT's latest filing, from $910.4 million in the prior quarter.
• Across five years, Current Assets topped out at $910.4 million in Q4 2025 and bottomed at $194.7 million in Q1 2022.
• Historically, Current Assets has averaged $372.8 million across 5 years, with a median of $296.5 million in 2024.
• Annual changes were most pronounced in 2025 — Current Assets sank 42.77% — and 2026, when it surged 247.12%.
• Cogent Biosciences' Current Assets stood at $265.0 million in 2022, then increased by 2.19% to $270.8 million in 2023, then advanced by 9.49% to $296.5 million in 2024, then soared by 207.06% to $910.4 million in 2025, then slipped by 3.58% to $877.8 million in 2026.
• Business Quant data shows COGT's Current Assets at $877.8 million in Q1 2026, $910.4 million in Q4 2025, and $397.2 million in Q3 2025.